-Description

Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ～3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.

Catalog No.

DHD10801

Host species

Chimeric

Species reactivity

Human

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

1 mg/ml

Purity

>95% by SDS-PAGE.

Clonality

Monoclonal

Isotype

IgG1-kappa

Applications

Research Grade Biosimilar

Target

CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

XtenCHO

Accession

P15391

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

CD19, SAR3419, CAS: 1269764-99-9

Note

For research use only. Not suitable for clinical or therapeutic use.